Sirius Therapeutics Announces Promising Phase I Clinical Data from Its Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders
Data presented at American Society of Hematology annual meeting
Sirius Therapeutics today announced promising preliminary data from its Phase 1 first-in-human clinical trial of SRSD107, a next generation siRNA therapeutics under clinical development for the prevention and treatment of thromboembolic disorders, such as myocardial infarction, ischemic stroke, and venous thromboembolism. The trial data were presented during a poster session at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, held in San Diego, CA.
SRSD107 is designed to inhibit Factor XI (FXI), a protein in the coagulation pathway that has shown potential to reduce thrombosis without significantly increasing the risk of bleeding, a major liability of current drugs.
“In this trial, SRSD107 was safe and well tolerated, with pharmacokinetic parameters consistent with a typical siRNA product,” said Dr. Patrick Yue, Sirius’ Chief Medical Officer. “We are encouraged by the marked, prolonged reduction in FXI antigen and activity, and increase in clotting, or thromboplastin time, that are consistent potent anticoagulation over sustained periods and reduced bleeding risk respectively. The trial provides a strong foundation for Phase 2 clinical studies.”
Dr. Qunsheng Ji, Sirius’ Chief Executive Officer added that “presentation of these findings at ASH 2024 underscores Sirius Therapeutics' commitment to advancing innovative treatments for thromboembolic disorders.”
The study was a single-site, randomized double-blind, placebo controlled study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of subcutaneously administered SRSD107 in 40 healthy subjects. Five cohorts, each consisting of eight subjects evaluated eight doses of SRSD107, each receiving either a single SRSD107 dose or placebo. In the trial, SRSD107 was safe and well-tolerated. Significant changes from baseline in PD biomarkers were observed, with maximal reductions in FXI antigen and activity > 90% and an aPTT (thromboplastin time) increase of > 100% (i.e., an aPTT ratio > 2.0) at the highest doses tested. The pharmacodynamic effects were durable, with FXI antigen and activity levels remaining suppressed for more than 16 weeks after dosing.
The study is titled, “A Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SRSD107 in Healthy Subjects. For more information on the study and our ongoing clinical trials, please visit Sirius Therapeutics' website (www.siriusrna.com) or here.
About Thromboembolic Disorders
Thrombosis, or blood clot formation, is the common underlying mechanism of most cases of myocardial infarction, ischemic stroke, and venous thromboembolism. According to a study in The Lancet of regional and global mortality rates, thromboembolic disorders are estimated to cause as many as 1 in 4 deaths worldwide.
About SRSD107
SRSD107 is a novel double-stranded small interfering ribonucleic acid (siRNA). Developed by Sirius Therapeutics, SRSD107 specifically targets human coagulation factor XI (FXI) mRNA and inhibits FXI protein expression, thereby blocking the intrinsic coagulation pathway and promoting anticoagulant/anti-thrombotic effects. SRSD107 has been engineered for the potential to enable once or twice-a-year dosing.
About Sirius Therapeutics
Sirius is an innovative, clinical stage biotech company developing next generation siRNA therapy for global markets. We are dedicated to translating siRNA technology into transformative medicine for patients with chronic diseases. Our most advanced products are SRSD107 for the treatment of thromboembolic disorders, and SRSD101 for the treatment of dyslipidemia. Founded in 2021 by a world-class leadership team and investors, Sirius has established an innovative discovery center in the United States and translational medicine center in China. Sirius has raised nearly US$100 million funding to date from OrbiMed, Creacion Ventures, Hankang Capital, Delos Capital, and the leadership team.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241209815845/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
InMotion Ventures Invests $2 Million in Cyclic Materials, Extending Series B to $55 Million23.1.2025 15:00:00 CET | Press release
The Series B funding will be used to support the opening of Cyclic Materials’ first commercial facilities in the US and Europe Cyclic Materials, the advanced recycling company building a circular supply chain for Rare Earth Elements and other critical materials, today announced a $2 million investment from InMotion Ventures, the investment arm of Jaguar Land Rover (JLR). This latest backing lifts the company’s Series B round to $55 million, underscoring its critical role in advancing sustainable supply chains for the automotive industry and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250123234060/en/ Cyclic Materials extracts REEs from various end-of-life products, including EVs, consumer electronics, and medical equipment. Pictured are recycled EV and hybrid vehicle motors. (Photo: Business Wire) Rare Earth Elements (REEs) are an essential component in permanent magnets, which are found in everything from data ce
Technology Holdings to Rebrand as TH Global Capital and Expand into Asset Management and Growth Advisory23.1.2025 14:56:00 CET | Press release
Technology Holdings, an award-winning global investment banking firm with operations in 13 countries across 5 continents including the Americas, Europe, and Asia-Pacific, announced that it will be rebranding to TH Global Capital. This rebrand reflects the firm’s continued expansion into additional sectors and products including Asset Management and an expanded Growth Advisory offering to create wealth for its clients. TH Global Capital, is designed to reflect the firm’s comprehensive offering, including Sell Side M&A, its Buy Side M&A practice 'TH Buy and Build', Growth Equity, Debt Financing, Financial Sponsor Coverage & Secondaries, IPO Advisory, Asset Management and Growth Advisory services. This includes the launch of TH Global Asset Management and an expanded growth advisory services offering, aimed at helping companies protect and grow their valuations through focused growth strategy advice. The firm also announced it's now becoming a purpose-driven company, with a singular purpo
SLB Capturi powers up its first modular carbon capture plant23.1.2025 14:26:00 CET | Press release
Plant will capture up to 100,000 metric tons of CO2 annually for Netherlands-based sustainable energy supplier Twence Global energy technology companySLB (NYSE: SLB) announced today that SLB Capturi has completed commissioning and is handing over its modular carbon capture plant at Twence’s waste-to-energy facility in Hengelo, Netherlands. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250123296222/en/ The new plant has the capacity to capture up to 100,000 metric tons of CO2 per year, which will be used in applications for the horticulture and food and beverage sectors. (Photo: Business Wire) The new plant has the capacity to capture up to 100,000 metric tons of CO2 per year, which will be used in applications for the horticulture and food and beverage sectors. The carbon capture plant is based on SLB Capturi’s standard, modular Just Catch™ design, which reduces onsite installation and outfitting work — providing a more cos
Syncron Accelerates Growth by Joining the AWS ISV Accelerate Program23.1.2025 14:00:00 CET | Press release
Syncron, a leading provider of intelligent Service Lifecycle Management solutions, announced today that it has joined the Amazon Web Services (AWS) Independent Software Vendor (ISV) Accelerate Program. This co-sell program supports AWS Partners that offer software solutions running on or integrating with AWS, connecting them with the AWS Sales organization to drive new business and accelerate sales cycles. Unlocking New Growth Opportunities with AWS By joining the AWS ISV Accelerate Program, Syncron gains focused co-selling support from AWS, as well as access to sales enablement resources, including educational events and solution libraries. Through this partnership, Syncron will collaborate closely with AWS Sales teams, providing better customer outcomes through its integrated and optimized cloud solutions for after-sales services. Joining the program also enhances Syncron's visibility within the AWS ecosystem, ensuring that AWS Account Managers can actively support the promotion and
Merck Partners with Opentrons Labworks, Inc., supporting Lab of the Future23.1.2025 14:00:00 CET | Press release
Custom robotic workstation automates company’s broad portfolio of biology assays for academia, biotech, and pharmaMeets growing need for autonomous tools that boost throughput and reproducibilityProvides customers with verified and automated workflows Merck, a leading science and technology company, and Opentrons Labworks, Inc., a leader in lab automation and accessible robotics, announced a multi-year agreement to automate assay kits on a custom Opentrons Flex® workstation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250123723506/en/ Custom Opentrons Flex® workstation available mid-2025 (Photo: Business Wire) Scientists and engineers will collaborate to develop and verify platform workflows utilizing Merck’s broad offering of automation-enabled assays. Together, the custom workstation and automation-enabled assays will deliver increased consistency and higher throughput by reducing manual processing and repetitive tasks
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom